Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 6/20 | 0.33 |
| ▸ | HTR3A | P46098 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2638261 | 0.79 | HRH3 (0.38) | HRH3KCNH2CHRNA7HTR3A | |
| SCHEMBL2639218 | 0.77 | HRH3 (0.37) | HRH3CHRNA7HTR3A | |
| SCHEMBL2637989 | 0.76 | HRH3 (0.34) | HRH3KCNH2CHRNA7HTR3A | |
| SCHEMBL2641493 | 0.76 | CHRNA7 (0.36) | HRH3KCNH2CHRNA7HTR3A | |
| SCHEMBL2638636 | 0.76 | HRH3 (0.36) | HRH3KCNH2CHRNA7HTR3A | |
| SCHEMBL2639305 | 0.75 | CHRNA7 (0.35) | HRH3KCNH2CHRNA7HTR3A | |
| SCHEMBL2639547 | 0.75 | S1PR1 (0.34) | HRH3KCNH2CHRNA7HTR3A | |
| SCHEMBL2641501 | 0.75 | HRH3 (0.36) | HRH3KCNH2CHRNA7HTR3A | |
| SCHEMBL2639548 | 0.74 | HRH3 (0.35) | HRH3KCNH2CHRNA7HTR3A | |
| SCHEMBL2641478 | 0.73 | HRH3 (0.35) | HRH3CHRNA7HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4711391-B2 | — | — | 2011-06-29 | — | — | JP | claimed |
| EP-1785425-A2 | Novel 1,4-diazabicycloalkane derivatives, their preparation and use | NeuroSearch A/S (DK) | 2007-05-16 | — | — | EP | claimed |
| US-20060122172-A1 | Novel 1,4-diazabicycloalkane derivatives, their preparation and use | DANPET AB (SE) | 2006-06-08 | — | — | US | claimed |
| EP-1551835-A1 | NOVEL 1,4-DIAZABICYCLOALKANE DERIVATIVES, THEIR PREPARATION AND USE | NeuroSearch A/S (DK) | 2005-07-13 | — | — | EP | claimed |
| WO-2004029053-A1 | NOVEL 1,4-DIAZABICYCLOALKANE DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2004-04-08 | — | — | WO | claimed |
| EP-1785425-B1 | 1,4-Diazabicycloalkane derivatives, their preparation and use | NEUROSEARCH AS (DK) | 2009-03-25 | — | — | EP | disclosed |
| US-7220741-B2 | 1,4-diazabicycloalkane derivatives, their preparation and use | NEUROSEARCH A/S (DK) | 2007-05-22 | — | — | US | disclosed |
| EP-1785425-A2 | Novel 1,4-diazabicycloalkane derivatives, their preparation and use | NeuroSearch A/S (DK) | 2007-05-16 | — | — | EP | disclosed |
| US-20060122172-A1 | Novel 1,4-diazabicycloalkane derivatives, their preparation and use | DANPET AB (SE) | 2006-06-08 | — | — | US | disclosed |
| EP-1551835-A1 | NOVEL 1,4-DIAZABICYCLOALKANE DERIVATIVES, THEIR PREPARATION AND USE | NeuroSearch A/S (DK) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004029053-A1 | NOVEL 1,4-DIAZABICYCLOALKANE DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122172-A1 | Novel 1,4-diazabicycloalkane derivatives, their preparation and use | CHRNA5, CHRNA7, CHRNA6 | HRH3 672/4885KCNH2 749/4885CHRNA7 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.